NCT06152809View on ClinicalTrials.gov

CIML NK Cells With Venetoclax for AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia RecurrentLeukemiaLeukemia, Myeloid
Interventions
BIOLOGICAL

Cytokine-Induced Memory-like Natural Killer Cells

Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.

BIOLOGICAL

Interleukin-2

Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.

DRUG

Venetoclax

Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.

Trial Locations (2)

02215

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER